Anti-IgE therapy inhibits chemotaxis, proliferation and transformation of circulating fibrocytes in patients with severe allergic asthma.
Chun-Hua WangChih-Ming WengTzu-Ting HuangMeng-Jung LeeChun-Yu LoMei-Chuan ChenChun-Liang ChouHan-Pin KuoPublished in: Respirology (Carlton, Vic.) (2021)
Omalizumab reduced the number of circulating fibrocytes, cell and number of fibrocytes as well as α-SMA+ fibrocytes after 3-7 days of culture in SAA patients. IL-33 and IL-13 may be implicated in the effectiveness of omalizumab in inhibiting fibrocyte activation contributing partly to the clinical benefits in reducing lamina propria and basement membrane thickening.
Keyphrases
- end stage renal disease
- signaling pathway
- ejection fraction
- chronic kidney disease
- randomized controlled trial
- newly diagnosed
- chronic obstructive pulmonary disease
- single cell
- systematic review
- peritoneal dialysis
- prognostic factors
- allergic rhinitis
- early onset
- cell therapy
- lung function
- patient reported outcomes
- mesenchymal stem cells
- air pollution
- drug induced
- bone marrow